Allosteric Modulator News Today

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 8, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced it had received written notification from The Nasdaq Stock Market LLC (Nasdaq) that it has regained compliance with the minimum bid price requirement of $1.00 per ADS under Nasdaq Listing Rule 5550(a)(2) and currently meets all other applicable cr

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 6, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it plans to change the ratio of its American Depositary Shares (“ADSs”) to its ordinary shares (the “ADS Ratio”) from the current ADS Ratio of one (1) ADS to six (6) ordinary shares to a new ADS Ratio of one (1) ADS...

Operator: Good morning and welcome to Cerevel Therapeutics Second Quarter Financial Results Conference Call. At this time, all participants are in listen-only mode.

Data published in Neuropharmacology shows mGlu2 PAMs attenuate oxycodone use and potential as a novel treatment for opioid use disorder Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 24, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced data showing that administration of a metabotropic glutamate 2 (mGlu2) positive allosteric modulator significantly

Cerevel Therapeutics to Host Inaugural Virtual R&D Event Cerevel Therapeutics to Host Inaugural Virtual R&D Event Event will focus on CVL-865, the Phase 2 GABA Positive Allosteric Modulator, and include an overview of key preclinical programs Live webcast scheduled for Thursday, January 28 from 9:00 to 11:00 a.m. EST CAMBRIDGE, Mass., Dec. 14, 2020 — Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced i...